Discover our findings and learn more about our trials.
See our pipeline for work planned and in progress
Discover our findings and learn more about our trials.
Human Clinical Trials
2024/01
2024/01
IMMUNOVIR:
HUMAN CLINICAL TRIAL PUBLISHED
IMMUNOVIR:
HUMAN CLINICAL TRIAL PUBLISHED
The role of nutritional support with probiotics in outpatients with symptomatic acute respiratory tract infections: a multicenter, randomized, double‑blind, placebo‑controlled dietary study.
2023/07
2023/07
GASTRO ONE BC300:
HUMAN CLINICAL TRIAL PUBLISHED
GASTRO ONE BC300:
HUMAN CLINICAL TRIAL PUBLISHED
The Efficacy and Safety of Single-Strain Probiotic Formulations Containing Bifidobacterium lactis or Bacillus coagulans in Adult Patients with Irritable Bowel Syndrome—A Randomized Double-Blind Placebo-Controlled Three-Arm Interventional Trial.
2023/07
2023/07
GASTRO ONE BI040:
HUMAN CLINICAL TRIAL PUBLISHED
GASTRO ONE BI040:
HUMAN CLINICAL TRIAL PUBLISHED
The Efficacy and Safety of Single-Strain Probiotic Formulations Containing Bifidobacterium lactis or Bacillus coagulans in Adult Patients with Irritable Bowel Syndrome—A Randomized Double-Blind Placebo-Controlled Three-Arm Interventional Trial.
In-vitro and significant findings
2024/03
2024/03
Gluten digest:
gluten hydrolysis
Gluten digest:
gluten hydrolysis
Reducing immmunoreactivity of gluten peptides by probiotic lactic acid bacteria for dietary management of gluten-related diseases.
2024/02
2024/02
NORDBIOTIC™ LPC100:
COMPLETE GENOME SEQUENCE
NORDBIOTIC™ LPC100:
COMPLETE GENOME SEQUENCE
Complete genome sequence of the probiotic Lacticaseibacillus paracasei LPC100 strain from NORDBIOTIC™ collection isolated from a human fecal sample.
2024/01
2024/01
NORDBIOTIC™ strain:
MIXTURE FOR GLUTEN DIGESTION
NORDBIOTIC™ strain:
MIXTURE FOR GLUTEN DIGESTION
Lacticaseibacillus casei LC130 strain, Lacticaseibacillus paracasei LPC100 strain, Streptococcus salivarius ssp. thermophilus ST250 strain – composition reducing the immunoreactivity of gliadin peptides and the use of strains for the production of the composition. Polish patent application no. P.447563
2023/10
2023/10
SCIENTIFIC RATIONAL OF STRAIN SELECTION FOR CHILDREN’S HEATH
SCIENTIFIC RATIONAL OF STRAIN SELECTION FOR CHILDREN’S HEATH
The effectiveness of selected Lactobacillus and Bifidobacterium strains for support the holistic health and well-being of children.
2023/05
2023/05
NORDBIOTIC™ BABY:
SCIENTIFIC RATIONAL OF STRAIN SELECTION
NORDBIOTIC™ BABY:
SCIENTIFIC RATIONAL OF STRAIN SELECTION
The effectiveness of selected lactobacillus and Bifidobacterium on infantile colic.
2023/05
2023/05
CLINICAL RATIONAL – NORDBIOTIC™ 5 STRAIN COMBINATION
CLINICAL RATIONAL – NORDBIOTIC™ 5 STRAIN COMBINATION
The effectiveness of selected Lactobacillus and Bifidobacterium lactis BI040 strains for support the health.
2023/05
2023/05
FEMAX:
ENHANCING IRON ABSORPTION
FEMAX:
ENHANCING IRON ABSORPTION
Development of a Multilayer Probiotic Tablet for Enhanced Iron Absorption: Harnessing the Potential of NORDBIOTIC™ LC130, LPC100.
2022/11
2022/11
RESISTANCE OF NORDBIOTIC™ STRAINS TO SELEN
RESISTANCE OF NORDBIOTIC™ STRAINS TO SELEN
Selection of NORDBIOTIC™ strains resistant to selenomethionine.
2022/10
2022/10
TARGET SHIELD NORDBIOTIC™:
PROTECTION OF MICROBIOME
TARGET SHIELD NORDBIOTIC™:
PROTECTION OF MICROBIOME
Development of specific NORDBIOTIC™ composition of strains for antibiotic therapy.